BURLINGTON, ON, Nov. 30 /CNW/ - The Jenex Corporation (TSX Venture
Exchange: JEN; Frankfurt: JNX - at Yahoo Finance, use JEN.V) announced that
interceptCS, the first product clinically proven and approved to prevent cold
sores was featured in Dr. Gifford-Jones column. Dr. Gifford-Jones column
appears in 52 newspapers across Canada. A copy of the article can be obtained
at www.edmontonsun.com/Lifestyle/Health/2007/11/24/4681630-sun or
Jenex Director of Sales and Marketing, Michael Mayo commented: "We are
excited that exposure from this article will greatly increase the product
awareness for interceptCS. This article along with the article in the December
issue of Canadian Living magazine will help inform cold sore sufferers there
is now a PREVENTION solution to their problem."
About The Jenex Corporation: Jenex has a non-invasive Medical Device that
prevents cold sore outbreaks. The interceptCS(TM) Cold Sore Prevention System
is approved in Canada and has received CE approval for European Union
countries. In addition to interceptCS, Jenex markets Therapik(R) for insect
stings & bites. Therapik(R) immediately relieves the pain & itch caused by
over 20,000 different insects. Therapik(R) is approved in Canada and the
United States and Australia, as well as having CE Mark approval in the
European Union countries.
Jenex's Thermal Therapy technology is patented in the U.S., Canada,
Australia, & Europe.
Check www.interceptCS.com and www.JenexCorp.com for details.
The TSX Venture Exchange Inc. has not reviewed and does not accept
responsibility for the accuracy or the contents of this press release. Certain
information included in this press release is forward-looking and is subject
to important risks and uncertainties. The results or events predicted in these
statements may differ materially from actual results or events.
For further information:
For further information: The Jenex Corporation, Michael A. Jenkins,
(905) 632-3830, Jenex@JenexCorp.com